| Literature DB >> 31921467 |
Soo-Jin Oh1, Jae Kyung Lee1, Ok Sarah Shin1.
Abstract
Immunosenescence is characterized by a progressive deterioration of the immune system associated with aging. Multiple components of both innate and adaptive immune systems experience aging-related changes, such as alterations in the number of circulating monocytic and dendritic cells, reduced phagocytic activities of neutrophils, limited diversity in B/T cell repertoire, T cell exhaustion or inflation, and chronic production of inflammatory cytokines known as inflammaging. The elderly are less likely to benefit from vaccinations as preventative measures against infectious diseases due to the inability of the immune system to mount a successful defense. Therefore, aging is thought to decrease the efficacy and effectiveness of vaccines, suggesting aging-associated decline in the immunogenicity induced by vaccination. In this review, we discuss aging-associated changes in the innate and adaptive immunity and the impact of immunosenescence on viral infection and immunity. We further explore recent advances in strategies to enhance the immunogenicity of vaccines in the elderly. Better understanding of the molecular mechanisms underlying immunosenescence-related immune dysfunction will provide a crucial insight into the development of effective elderly-targeted vaccines and immunotherapies.Entities:
Keywords: Aging; Immunosenescence; Vaccines; Viral infections
Year: 2019 PMID: 31921467 PMCID: PMC6943173 DOI: 10.4110/in.2019.19.e37
Source DB: PubMed Journal: Immune Netw ISSN: 1598-2629 Impact factor: 6.303
Figure 1Multiple factors involved in aging. The diagram highlights multiple factors involved in aging; genomic instability, telomere attrition, epigenetic alterations, sarcopenia, changes in intracellular communication, cellular senescence, immunosenescence, and mitochondrial dysfunction.
Summary of the immune changes associated with aging
| Immunity | Cell | Aging-associated changes |
|---|---|---|
| Innate | Monocytes/macrophages | - Reduced phagocytic activity |
| - Decreased MHC II expression | ||
| - Decreased ROS and cytokine production | ||
| - Altered TLR expression (decreased except for TLR5) | ||
| DCs | - Decreased maturation and Ag presentation | |
| - Altered TLR expression and signaling | ||
| - Impaired Ag uptake | ||
| - Altered CD80 and CD86 expression | ||
| Neutrophils | - Reduced chemotaxis | |
| - Decreased MHC II expression | ||
| - Decreased ROS and cytokine production | ||
| - Altered TLR expression | ||
| - Decreased NET formation | ||
| Adaptive | B cells | - Limited diversity in BCR repertoire |
| - Decreased numbers of naïve and circulating B cells | ||
| - Reduced Ag-specific Ab production | ||
| - Altered memory B cell homeostasis | ||
| T cells | - Restricted diversity in TCR repertoire | |
| - Decreased numbers of naïve T cells | ||
| - Increased numbers of senescent T cells | ||
| - Increased numbers of exhausted T cells | ||
| - Expansion of inflationary CD8+ T cell populations caused by chronic viral infections (CMV, EBV) | ||
| - Diminished effector T cell response to new Ag |
BCR, B cell receptor; EBV, Epstein-Barr virus.
Figure 2The impact of immunosenescence on persistent viral infection and immunity. Aging leads to numerous changes in major components of both the innate and adaptive immune systems. In response to a viral infection, innate immune cells can trigger the activation of IFN pathways to clear the virus-infected cells. Age-associated defects in innate immune cells can lead to reduced IFN production. Persistent viral infection, such as CMV persistence, can have a profound effect on alterations in adaptive immunity, in particular, T cell composition and function. In the elderly, there are decreased numbers of naïve T cells, but increased numbers of senescent, inflationary, or exhausted T cells that are functionally inert or dormant.
Strategies towards more effective vaccines for the elderly
| Infectious diseases | Vaccine strategies | Potential mechanisms |
|---|---|---|
| Influenza | Increased amount of Ags | Increased Ag availability |
| Quadrivalent instead of trivalent strains | - Increased immunogenicity | |
| - Avoid vaccine mismatch | ||
| Repeated vaccinations | Increased immunogenicity | |
| Mucosal or subcutaneous microneedle-intradermal administration | Increased efficiency of vaccine delivery | |
| Adjuvants (MF59, AS03) | - Increased Ag presentation activities | |
| - Enhanced immunogenicity | ||
| Shingles | Increased viral titers for VZV live-attenuated shingles vaccines (>10 times higher titers than chickenpox vaccines) | Increased Ag availability |
| Major Ag with adjuvants (Subunit glycoprotein E vaccine with AS01) | Induction of robust and persistent VZV-specific Ab and CD4+ T cell responses |